Atara Biotherapeutics Inc. (NASDAQ:ATRA) fell 2.3% during mid-day trading on Wednesday following insider selling activity. The stock traded as low as $19.49 and last traded at $19.77, with a volume of 62,204 shares changing hands. The stock had previously closed at $20.23.

Specifically, insider Christopher Haqq sold 1,346 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $22.32, for a total value of $30,042.72. Following the transaction, the insider now directly owns 295,294 shares of the company’s stock, valued at approximately $6,590,962.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 9,600 shares of the firm’s stock in a transaction that occurred on Friday, July 8th. The stock was sold at an average price of $22.88, for a total transaction of $219,648.00. Following the completion of the transaction, the chief executive officer now directly owns 223,228 shares in the company, valued at $5,107,456.64. The disclosure for this sale can be found here. 16.10% of the stock is currently owned by corporate insiders.

A number of research firms have weighed in on ATRA. JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Jefferies Group reissued a “buy” rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a research note on Sunday, July 10th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 19th. Citigroup Inc. raised their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research note on Friday, August 19th. Finally, Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $23.00 to $16.00 in a research note on Thursday, September 15th. Three equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Atara Biotherapeutics has an average rating of “Hold” and a consensus price target of $26.14.

The firm has a 50-day moving average price of $21.14 and a 200-day moving average price of $20.02. The firm’s market cap is $589.47 million.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.05. On average, equities research analysts predict that Atara Biotherapeutics Inc. will post ($2.85) earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC increased its position in Atara Biotherapeutics by 4.2% in the second quarter. ProShare Advisors LLC now owns 24,236 shares of the company’s stock worth $546,000 after buying an additional 980 shares in the last quarter. JPMorgan Chase & Co. increased its position in Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock worth $1,191,000 after buying an additional 1,900 shares in the last quarter. BlackRock Group LTD increased its position in Atara Biotherapeutics by 76.8% in the first quarter. BlackRock Group LTD now owns 5,400 shares of the company’s stock worth $103,000 after buying an additional 2,345 shares in the last quarter. BlackRock Advisors LLC increased its position in Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock worth $229,000 after buying an additional 2,361 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in Atara Biotherapeutics by 23.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 16,200 shares of the company’s stock worth $365,000 after buying an additional 3,100 shares in the last quarter. 75.50% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.